**Abpro Holdings, Inc. Reports Financial Results and Operational Updates in Form 10-K Filing**

Abpro Holdings, Inc., a biotechnology company focused on developing next-generation antibody therapeutics, filed its Form 10-K for the year ended December 31, 2025, detailing its financial performance and operational activities. The company reported no revenue for the year, a decrease from the $183,000 in research and development services revenue earned in 2024. This decline was attributed to the completion of research and development services performed for Celltrion related to ABP-102 development, with no similar revenue generated in 2025. The company's net loss for 2025 was $2.9 million, compared to a net loss of $7.2 million in 2024.

Operating expenses for Abpro decreased by 16% to $8.5 million in 2025, from $10.1 million in the previous year. Research and development expenses saw a significant reduction of 67%, falling to $989,000 due to personnel furloughs and subsequent terminations. General and administrative expenses, however, increased by 5% to $7.5 million, primarily driven by costs associated with operating as a public company. Other income, net, increased significantly to $5.6 million in 2025, compared to $2.7 million in 2024, mainly due to the derecognition of a $4.4 million liability for excise taxes payable and a $3.3 million derecognition of Mabwell liability, partially offset by $1.1 million in interest expenses and $0.8 million loss on the change in fair value of embedded derivative liability related the convertible notes.

Key operational developments included the FDA clearance of the Investigational New Drug (IND) application for ABP-102, the company's lead multispecific antibody oncology program, in collaboration with Celltrion. This clearance enables the initiation of a Phase 1 clinical trial for ABP-102 in patients with HER2-positive solid tumors. The company also continued to advance its ABP-201 program for vascular diseases of the eye. However, the company's Common Stock was delisted from NASDAQ in February 2026 and is now trading on the OTC Pink Limited Market.

Abpro's financial position remains challenging, with management expressing substantial doubt about the company's ability to continue as a going concern. As of December 31, 2025, the company had cash of $67,000 and an accumulated deficit of $119.0 million. The company's ability to continue operations is dependent on securing additional funding through equity or debt financings, collaboration agreements, or research grants. The company is actively pursuing these options, but there is no guarantee of success. The 10-K filing includes a cautionary note regarding forward-looking statements, highlighting the risks and uncertainties associated with drug development, regulatory approvals, and commercialization efforts.

About Abpro Holdings, Inc.

Abpro Holdings, Inc. is a biotechnology company developing next-generation antibody therapeutics for immuno-oncology and ophthalmology. Utilizing proprietary DiversImmune® and MultiMab™ platforms, it engineers multi-specific antibodies, including its TetraBi format, to target diseases like HER2+ solid tumors and vascular eye disorders. The company advances a pipeline of antibody candidates through strategic global partnerships, focusing on improved efficacy, safety, and dosing convenience in large, unmet medical markets.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov